Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Interim data from an ongoing Phase IIb trial of XL880 showed that 15 of 19 evaluable patients had decreases in tumor
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury